急性呼吸窘迫综合征患者动脉二氧化碳管理及其影响:LUNG SAFE研究的启示
该研究基于LUNG SAFE国际多中心观察性研究,分析2813例早期ARDS患者第1天及持续(第1天和第2天)低碳酸血症(PaCO2<35 mm Hg)、正常碳酸血症(PaCO2 35-45 mm Hg)和高碳酸血症(PaCO2>45 mm Hg)的患病率及其对管理和结局的影响。第1天低碳酸血症551例(19.6%)、正常碳酸血症1018例(36.2%)、高碳酸血症1214例(43.2%);持续低碳酸血症252例(9.3%)、持续正常碳酸血症544例(19.3%)、持续高碳酸血症654例(24.1%)。低碳酸血症在接受无创通气的患者中更常见且更严重,但也见于控制性机械通气患者。持续低碳酸血症在中低收入国家更常见,持续高碳酸血症在欧洲更常见。持续高碳酸血症患者ARDS严重程度最高且接受更多保护性通气。动脉CO2与结局无独立关联;倾向匹配分析中持续正常碳酸血症与持续高碳酸血症患者医院死亡率均为36%(P=1.0)。轻中度ARDS接受持续低碳酸血症者ICU死亡率(38.1%)高于正常碳酸血症者(27.1%)。
要点
- 轻中度ARDS患者持续低碳酸血症(第1天和第2天PaCO2<35 mm Hg)ICU死亡率为38.1%,高于持续正常碳酸血症的27.1%。
- 持续高碳酸血症患者ARDS严重程度最高且接受更多保护性通气,但倾向匹配分析中医院死亡率与持续正常碳酸血症均为36%(P=1.0)。
- 第1天低碳酸血症患病率为19.6%(95%CI 18.1-21.1),持续低碳酸血症为9.3%(95%CI 8.2-10.4)。
- 低碳酸血症在接受无创通气的患者中更常见且更严重,但也见于控制性机械通气患者。
- 动脉CO2与结局无独立关联;高碳酸血症无获益或伤害证据,但持续低碳酸血症在轻中度ARDS中值得关注。
适用人群与场景
- LUNG SAFE研究纳入的早期ARDS患者,分析2813例。
- 低碳酸血症在接受无创通气的患者中更常见且更严重,但也见于控制性机械通气患者。
- 持续低碳酸血症在中低收入国家更常见,持续高碳酸血症在欧洲更常见。
诊断标准与关键阈值
- 低碳酸血症:PaCO2<35 mm Hg;正常碳酸血症:PaCO2 35-45 mm Hg;高碳酸血症:PaCO2>45 mm Hg。
- 持续状态定义为第1天和第2天均符合上述PaCO2分类。
研究设计与关键结果
- 研究类型为国际多中心观察性研究(LUNG SAFE),分析2813例早期ARDS患者。
- 第1天低碳酸血症551例(19.6%;95%CI 18.1-21.1),正常碳酸血症1018例(36.2%;95%CI 34.4-38.0),高碳酸血症1214例(43.2%;95%CI 41.3-45.0)。
- 持续低碳酸血症252例(9.3%;95%CI 8.2-10.4),持续正常碳酸血症544例(19.3%;95%CI 17.9-20.8),持续高碳酸血症654例(24.1%;95%CI 22.5-25.7)。
- 持续高碳酸血症患者ARDS严重程度最高,且接受更多保护性通气。
- 动脉CO2与结局无独立关联;倾向匹配分析中持续正常碳酸血症与持续高碳酸血症患者医院死亡率均为36%(P=1.0)。
- 轻中度ARDS接受持续低碳酸血症者ICU死亡率为38.1%,高于正常碳酸血症者的27.1%。
证据类型、等级与局限
- 证据类型:国际多中心观察性研究(LUNG SAFE)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在轻中度ARDS患者中,持续低碳酸血症与ICU死亡率升高相关,提示需关注PaCO2管理。
- 高碳酸血症无获益或伤害证据,不应据此刻意追求或避免高碳酸血症。
- 接受无创通气的ARDS患者低碳酸血症更常见且更严重,应加强PaCO2监测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Considerable variability exists regarding CO2 management in early ARDS, with the impact of arterial CO2 tension on management and outcomes poorly understood.
RESEARCH QUESTION: To determine the prevalence and impact of hypocapnia and hypercapnia on the management and outcomes of patients with early ARDS enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study, an international multicenter observational study.
STUDY DESIGN AND METHODS: Our primary objective was to examine the prevalence of day 1 and sustained (day 1 and 2) hypocapnia (Paco2 < 35 mm Hg), normocapnia (Paco2 35-45 mm Hg), and hypercapnia (Paco2 > 45 mm Hg) in patients with ARDS. Secondary objectives included elucidating the effect of CO2 tension on ventilatory management and examining the relationship with ARDS outcome.
RESULTS: Of 2,813 patients analyzed, 551 (19.6%; 95%CI, 18.1-21.1) were hypocapnic, 1,018 (36.2%; 95% CI, 34.4-38.0) were normocapnic, and 1,214 (43.2%; 95% CI, 41.3-45.0) were hypercapnic, on day 1. Sustained hypocapnia was seen in 252 (9.3%; 95% CI, 8.2-10.4), sustained normocapnia in 544 (19.3%; 95% CI, 17.9-20.8), and sustained hypercapnia in 654 (24.1%; 95% CI, 22.5-25.7) patients. Hypocapnia was more frequent and severe in patients receiving noninvasive ventilation but also was observed in patients on controlled mechanical ventilation. Sustained hypocapnia was more frequent in middle-income countries, whereas sustained hypercapnia was more frequent in Europe. ARDS severity profile was highest in sustained hypercapnia, and these patients received more protective ventilation. No independent association was seen between arterial CO2 and outcome. In propensity-matched analyses, the hospital mortality rate was 36% in both sustained normocapnic and hypercapnic patients (P = 1.0). ICU mortality was higher in patients with mild to moderate ARDS receiving sustained hypocapnia (38.1%) compared with normocapnia (27.1%).
INTERPRETATION: No evidence was found for benefit or harm with hypercapnia. Of concern, ICU mortality was higher with sustained hypocapnia in mild to moderate ARDS.
参考来源
- Madotto F, Rezoagli E, McNicholas BA, et al. Patterns and Impact of Arterial CO2 Management in Patients With Acute Respiratory Distress Syndrome: Insights From the LUNG SAFE Study. Chest. 2020. PMID: 32589951. doi:10.1016/j.chest.2020.05.605
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。